Globe Newswire10.05.17
Inspire Medical Systems Inc., manufacturer of the only U.S. Food and Drug Administration (FDA)-approved active implantable device for obstructive sleep apnea (OSA), has announced five-year results of its pivotal STAR clinical trial. The trial results demonstrated that the significant improvements derived by patients utilizing Inspire therapy were sustained following five years of continued use.
“The five-year results from the STAR clinical trial are the most significant to date demonstrating the durable long-term improvement in objective and patient-reported outcomes with Inspire therapy,” said B. Tucker Woodson, M.D., of Froedtert Hospital & the Medical College of Wisconsin. “The investigating physicians involved in the study continue to conclude that, in CPAP intolerant sleep apnea patients who meet inclusion criteria, cranial nerve stimulation with Inspire therapy provides safe and sustained benefit.”
The presentation of the STAR 5-year results highlighted:
“Consistent and predictable patient outcomes are the priorities for Inspire therapy, and the foundation for continued growth in its adoption,” stated Inspire President and CEO Tim Herbert. “As such, we are excited about the growing body of clinical evidence showing Inspire therapy to be a safe and effective therapy for CPAP-intolerant patients, and are committed to expanding its use with sleep apnea patients globally.”
Inspire also has launched the ADHERE Registry to evaluate 2,500 Inspire therapy patients in the United States and Europe. Early data on 259 patients from the ADHERE Registry were recently presented and demonstrated positive results in patient outcomes and therapy adherence that are consistent with the STAR clinical trial.
“The ADHERE Registry is the largest collective report on the performance of Inspire therapy at leading medical centers in the world,” said Maurits Boon, M.D., of the Thomas Jefferson University Hospital (TJUH) in Philadelphia, Pa. “Initial patient outcomes have been compelling to date, and we look forward to continuing to enroll patients in this important registry study.”
Finally, an independent clinical study conducted at TJUH and the University of Pittsburgh Medical Center (UPMC) entitled, “Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea; An Evaluation and Comparison of Outcomes at Two Academic Centers” was published online over the summer in the Journal of Clinical Sleep Medicine. This publication included data on 97 Inspire therapy patients which demonstrated that the treatment improves both objective and subjective patient outcomes.
The results from the publication include:
Inspire Upper Airway Stimulation therapy, or also known as Cranial Nerve (XII) stimulation therapy, is an FDA-approved treatment for some people with moderate to severe obstructive sleep apnea who are unable to use or get consistent benefit from continuous positive airway pressure (CPAP). In contrast to CPAP, Inspire therapy is implanted inside the body and works with a patient's natural breathing process. Controlled by the small handheld sleep remote, the system includes a breathing sensor and a stimulation lead powered by a neurostimulator. During sleep, the Inspire system senses breathing patterns and delivers mild stimulation to the tongue and other soft tissues of the throat to keep the airway open. nspire therapy is currently available at over 100 medical centers across the United States and Europe.
Inspire Medical Systems Inc., based in Minneapolis, Minn., develops therapy to help OSA patients who are unable to tolerate or get relief from CPAP. Inspire therapy is the world’s first implantable FDA-approved neurostimulation system for the treatment of OSA. The company is privately held and investors include Amzak Health, Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.
“The five-year results from the STAR clinical trial are the most significant to date demonstrating the durable long-term improvement in objective and patient-reported outcomes with Inspire therapy,” said B. Tucker Woodson, M.D., of Froedtert Hospital & the Medical College of Wisconsin. “The investigating physicians involved in the study continue to conclude that, in CPAP intolerant sleep apnea patients who meet inclusion criteria, cranial nerve stimulation with Inspire therapy provides safe and sustained benefit.”
The presentation of the STAR 5-year results highlighted:
- Significant reduction in the severity of patients’ OSA
- Significant improvements in sleep-related quality of life
- Statistically significant reduction in snoring
- Eighty percent of patients in the study at five years used the device every night
“Consistent and predictable patient outcomes are the priorities for Inspire therapy, and the foundation for continued growth in its adoption,” stated Inspire President and CEO Tim Herbert. “As such, we are excited about the growing body of clinical evidence showing Inspire therapy to be a safe and effective therapy for CPAP-intolerant patients, and are committed to expanding its use with sleep apnea patients globally.”
Inspire also has launched the ADHERE Registry to evaluate 2,500 Inspire therapy patients in the United States and Europe. Early data on 259 patients from the ADHERE Registry were recently presented and demonstrated positive results in patient outcomes and therapy adherence that are consistent with the STAR clinical trial.
“The ADHERE Registry is the largest collective report on the performance of Inspire therapy at leading medical centers in the world,” said Maurits Boon, M.D., of the Thomas Jefferson University Hospital (TJUH) in Philadelphia, Pa. “Initial patient outcomes have been compelling to date, and we look forward to continuing to enroll patients in this important registry study.”
Finally, an independent clinical study conducted at TJUH and the University of Pittsburgh Medical Center (UPMC) entitled, “Upper Airway Stimulation for Treatment of Obstructive Sleep Apnea; An Evaluation and Comparison of Outcomes at Two Academic Centers” was published online over the summer in the Journal of Clinical Sleep Medicine. This publication included data on 97 Inspire therapy patients which demonstrated that the treatment improves both objective and subjective patient outcomes.
The results from the publication include:
- Significant reductions in sleep apnea severity in all patients
- Significant improvements in quality of life measures in all patients
- Objective report of therapy use of over 40 hours per week
Inspire Upper Airway Stimulation therapy, or also known as Cranial Nerve (XII) stimulation therapy, is an FDA-approved treatment for some people with moderate to severe obstructive sleep apnea who are unable to use or get consistent benefit from continuous positive airway pressure (CPAP). In contrast to CPAP, Inspire therapy is implanted inside the body and works with a patient's natural breathing process. Controlled by the small handheld sleep remote, the system includes a breathing sensor and a stimulation lead powered by a neurostimulator. During sleep, the Inspire system senses breathing patterns and delivers mild stimulation to the tongue and other soft tissues of the throat to keep the airway open. nspire therapy is currently available at over 100 medical centers across the United States and Europe.
Inspire Medical Systems Inc., based in Minneapolis, Minn., develops therapy to help OSA patients who are unable to tolerate or get relief from CPAP. Inspire therapy is the world’s first implantable FDA-approved neurostimulation system for the treatment of OSA. The company is privately held and investors include Amzak Health, Aperture Venture Partners, GDN Holdings, Johnson & Johnson, Kleiner Perkins Caufield & Byers, Medtronic, OrbiMed Advisors, Synergy Life Science Partners, TGap Ventures and US Venture Partners.